 | • レポートコード：GIR-2104Z03817 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、COPD（慢性閉塞性肺疾患）治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。COPD（慢性閉塞性肺疾患）治療薬の種類別市場規模（気管支拡張薬、PDE-4阻害薬、ステロイド、併用療法、その他）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・COPD（慢性閉塞性肺疾患）治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Novartis、GlaxoSmithKline、Merck、Abbott Laboratories、Boehringer Ingelheim、AstraZeneca、Roche Holding AG、Teva Pharmaceutical Industries、Vectura Group、Mylan NV ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：気管支拡張薬、PDE-4阻害薬、ステロイド、併用療法、その他 ・用途別分析2016年-2026年：病院、診療所、その他 ・COPD（慢性閉塞性肺疾患）治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・COPD（慢性閉塞性肺疾患）治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・COPD（慢性閉塞性肺疾患）治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・COPD（慢性閉塞性肺疾患）治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・COPD（慢性閉塞性肺疾患）治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The COPD Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global COPD Drugs size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global COPD Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
COPD Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Bronchodilators
PDE-4 Inhibitors
Steroids
Combination Therapies
Others
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
Pfizer
Novartis
GlaxoSmithKline
Merck
Abbott Laboratories
Boehringer Ingelheim
AstraZeneca
Roche Holding AG
Teva Pharmaceutical Industries
Vectura Group
Mylan NV
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of COPD Drugs
1.2 Classification of COPD Drugs by Type
1.2.1 Overview: Global COPD Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global COPD Drugs Revenue Market Share by Type in 2020
1.2.3 Bronchodilators
1.2.4 PDE-4 Inhibitors
1.2.5 Steroids
1.2.6 Combination Therapies
1.2.7 Others
1.3 Global COPD Drugs Market by Application
1.3.1 Overview: Global COPD Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global COPD Drugs Market Size & Forecast
1.5 Global COPD Drugs Market Size and Forecast by Region
1.5.1 Global COPD Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global COPD Drugs Market Size by Region, (2016-2021)
1.5.3 North America COPD Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe COPD Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific COPD Drugs Market Size and Prospect (2016-2026)
1.5.6 South America COPD Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa COPD Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 COPD Drugs Market Drivers
1.6.2 COPD Drugs Market Restraints
1.6.3 COPD Drugs Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer COPD Drugs Product and Solutions
2.1.4 Pfizer COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis COPD Drugs Product and Solutions
2.2.4 Novartis COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novartis Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline COPD Drugs Product and Solutions
2.3.4 GlaxoSmithKline COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck COPD Drugs Product and Solutions
2.4.4 Merck COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Merck Recent Developments and Future Plans
2.5 Abbott Laboratories
2.5.1 Abbott Laboratories Details
2.5.2 Abbott Laboratories Major Business
2.5.3 Abbott Laboratories COPD Drugs Product and Solutions
2.5.4 Abbott Laboratories COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Abbott Laboratories Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim COPD Drugs Product and Solutions
2.6.4 Boehringer Ingelheim COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca COPD Drugs Product and Solutions
2.7.4 AstraZeneca COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 AstraZeneca Recent Developments and Future Plans
2.8 Roche Holding AG
2.8.1 Roche Holding AG Details
2.8.2 Roche Holding AG Major Business
2.8.3 Roche Holding AG COPD Drugs Product and Solutions
2.8.4 Roche Holding AG COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Roche Holding AG Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries
2.9.1 Teva Pharmaceutical Industries Details
2.9.2 Teva Pharmaceutical Industries Major Business
2.9.3 Teva Pharmaceutical Industries COPD Drugs Product and Solutions
2.9.4 Teva Pharmaceutical Industries COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.10 Vectura Group
2.10.1 Vectura Group Details
2.10.2 Vectura Group Major Business
2.10.3 Vectura Group COPD Drugs Product and Solutions
2.10.4 Vectura Group COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Vectura Group Recent Developments and Future Plans
2.11 Mylan NV
2.11.1 Mylan NV Details
2.11.2 Mylan NV Major Business
2.11.3 Mylan NV COPD Drugs Product and Solutions
2.11.4 Mylan NV COPD Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Mylan NV Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global COPD Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 COPD Drugs Players Market Share
3.2.2 Top 10 COPD Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 COPD Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global COPD Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global COPD Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global COPD Drugs Revenue Market Share by Application (2016-2021)
5.2 COPD Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America COPD Drugs Revenue by Type (2016-2026)
6.2 North America COPD Drugs Revenue by Application (2016-2026)
6.3 North America COPD Drugs Market Size by Country
6.3.1 North America COPD Drugs Revenue by Country (2016-2026)
6.3.2 United States COPD Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada COPD Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico COPD Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe COPD Drugs Revenue by Type (2016-2026)
7.2 Europe COPD Drugs Revenue by Application (2016-2026)
7.3 Europe COPD Drugs Market Size by Country
7.3.1 Europe COPD Drugs Revenue by Country (2016-2026)
7.3.2 Germany COPD Drugs Market Size and Forecast (2016-2026)
7.3.3 France COPD Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom COPD Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia COPD Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy COPD Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific COPD Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific COPD Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific COPD Drugs Market Size by Region
8.3.1 Asia-Pacific COPD Drugs Revenue by Region (2016-2026)
8.3.2 China COPD Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan COPD Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea COPD Drugs Market Size and Forecast (2016-2026)
8.3.5 India COPD Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia COPD Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia COPD Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America COPD Drugs Revenue by Type (2016-2026)
9.2 South America COPD Drugs Revenue by Application (2016-2026)
9.3 South America COPD Drugs Market Size by Country
9.3.1 South America COPD Drugs Revenue by Country (2016-2026)
9.3.2 Brazil COPD Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina COPD Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa COPD Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa COPD Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa COPD Drugs Market Size by Country
10.3.1 Middle East & Africa COPD Drugs Revenue by Country (2016-2026)
10.3.2 Turkey COPD Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia COPD Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE COPD Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global COPD Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global COPD Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market COPD Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global COPD Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global COPD Drugs Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer COPD Drugs Product and Solutions
Table 9. Pfizer COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis COPD Drugs Product and Solutions
Table 13. Novartis COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline COPD Drugs Product and Solutions
Table 17. GlaxoSmithKline COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Merck Corporate Information, Head Office, and Major Competitors
Table 19. Merck Major Business
Table 20. Merck COPD Drugs Product and Solutions
Table 21. Merck COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 23. Abbott Laboratories Major Business
Table 24. Abbott Laboratories COPD Drugs Product and Solutions
Table 25. Abbott Laboratories COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 27. Boehringer Ingelheim Major Business
Table 28. Boehringer Ingelheim COPD Drugs Product and Solutions
Table 29. Boehringer Ingelheim COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 31. AstraZeneca Major Business
Table 32. AstraZeneca COPD Drugs Product and Solutions
Table 33. AstraZeneca COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Roche Holding AG Corporate Information, Head Office, and Major Competitors
Table 35. Roche Holding AG Major Business
Table 36. Roche Holding AG COPD Drugs Product and Solutions
Table 37. Roche Holding AG COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 39. Teva Pharmaceutical Industries Major Business
Table 40. Teva Pharmaceutical Industries COPD Drugs Product and Solutions
Table 41. Teva Pharmaceutical Industries COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Vectura Group Corporate Information, Head Office, and Major Competitors
Table 43. Vectura Group Major Business
Table 44. Vectura Group COPD Drugs Product and Solutions
Table 45. Vectura Group COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Mylan NV Corporate Information, Head Office, and Major Competitors
Table 47. Mylan NV Major Business
Table 48. Mylan NV COPD Drugs Product and Solutions
Table 49. Mylan NV COPD Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Global COPD Drugs Revenue (USD Million) by Players (2019-2021)
Table 51. Global COPD Drugs Revenue Share by Players (2019-2021)
Table 52. Breakdown of COPD Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. COPD Drugs Players Head Office, Products and Services Provided
Table 54. COPD Drugs Mergers & Acquisitions in the Past Five Years
Table 55. COPD Drugs New Entrants and Expansion Plans
Table 56. Global COPD Drugs Revenue (USD Million) by Type (2016-2021)
Table 57. Global COPD Drugs Revenue Share by Type (2016-2021)
Table 58. Global COPD Drugs Revenue Forecast by Type (2021-2026)
Table 59. Global COPD Drugs Revenue by Application (2016-2021)
Table 60. Global COPD Drugs Revenue Forecast by Application (2021-2026)
Table 61. North America COPD Drugs Revenue by Type (2016-2021) & (USD Million)
Table 62. North America COPD Drugs Revenue by Type (2021-2026) & (USD Million)
Table 63. North America COPD Drugs Revenue by Application (2016-2021) & (USD Million)
Table 64. North America COPD Drugs Revenue by Application (2021-2026) & (USD Million)
Table 65. North America COPD Drugs Revenue by Country (2016-2021) & (USD Million)
Table 66. North America COPD Drugs Revenue by Country (2021-2026) & (USD Million)
Table 67. Europe COPD Drugs Revenue by Type (2016-2021) & (USD Million)
Table 68. Europe COPD Drugs Revenue by Type (2021-2026) & (USD Million)
Table 69. Europe COPD Drugs Revenue by Application (2016-2021) & (USD Million)
Table 70. Europe COPD Drugs Revenue by Application (2021-2026) & (USD Million)
Table 71. Europe COPD Drugs Revenue by Country (2016-2021) & (USD Million)
Table 72. Europe COPD Drugs Revenue by Country (2021-2026) & (USD Million)
Table 73. Asia-Pacific COPD Drugs Revenue by Type (2016-2021) & (USD Million)
Table 74. Asia-Pacific COPD Drugs Revenue by Type (2021-2026) & (USD Million)
Table 75. Asia-Pacific COPD Drugs Revenue by Application (2016-2021) & (USD Million)
Table 76. Asia-Pacific COPD Drugs Revenue by Application (2021-2026) & (USD Million)
Table 77. Asia-Pacific COPD Drugs Revenue by Region (2016-2021) & (USD Million)
Table 78. Asia-Pacific COPD Drugs Revenue by Region (2021-2026) & (USD Million)
Table 79. South America COPD Drugs Revenue by Type (2016-2021) & (USD Million)
Table 80. South America COPD Drugs Revenue by Type (2021-2026) & (USD Million)
Table 81. South America COPD Drugs Revenue by Application (2016-2021) & (USD Million)
Table 82. South America COPD Drugs Revenue by Application (2021-2026) & (USD Million)
Table 83. South America COPD Drugs Revenue by Country (2016-2021) & (USD Million)
Table 84. South America COPD Drugs Revenue by Country (2021-2026) & (USD Million)
Table 85. Middle East & Africa COPD Drugs Revenue by Type (2016-2021) & (USD Million)
Table 86. Middle East & Africa COPD Drugs Revenue by Type (2021-2026) & (USD Million)
Table 87. Middle East & Africa COPD Drugs Revenue by Application (2016-2021) & (USD Million)
Table 88. Middle East & Africa COPD Drugs Revenue by Application (2021-2026) & (USD Million)
Table 89. Middle East & Africa COPD Drugs Revenue by Country (2016-2021) & (USD Million)
Table 90. Middle East & Africa COPD Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. COPD Drugs Picture
Figure 2. Global COPD Drugs Revenue Market Share by Type in 2020
Figure 3. Bronchodilators
Figure 4. PDE-4 Inhibitors
Figure 5. Steroids
Figure 6. Combination Therapies
Figure 7. Others
Figure 8. COPD Drugs Revenue Market Share by Application in 2020
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Others Picture
Figure 12. Global COPD Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global COPD Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global COPD Drugs Revenue Market Share by Region (2016-2026)
Figure 15. Global COPD Drugs Revenue Market Share by Region in 2020
Figure 16. North America COPD Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe COPD Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific COPD Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America COPD Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. COPD Drugs Market Drivers
Figure 21. COPD Drugs Market Restraints
Figure 22. COPD Drugs Market Trends
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Novartis Recent Developments and Future Plans
Figure 25. GlaxoSmithKline Recent Developments and Future Plans
Figure 26. Merck Recent Developments and Future Plans
Figure 27. Abbott Laboratories Recent Developments and Future Plans
Figure 28. Boehringer Ingelheim Recent Developments and Future Plans
Figure 29. AstraZeneca Recent Developments and Future Plans
Figure 30. Roche Holding AG Recent Developments and Future Plans
Figure 31. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 32. Vectura Group Recent Developments and Future Plans
Figure 33. Mylan NV Recent Developments and Future Plans
Figure 35. Global COPD Drugs Revenue Share by Players in 2020
Figure 36. COPD Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players COPD Drugs Revenue Market Share in 2020
Figure 38. Global Top 10 Players COPD Drugs Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global COPD Drugs Revenue Share by Type in 2020
Figure 41. Global COPD Drugs Market Share Forecast by Type (2021-2026)
Figure 42. Global COPD Drugs Revenue Share by Application in 2020
Figure 43. Global COPD Drugs Market Share Forecast by Application (2021-2026)
Figure 44. North America COPD Drugs Sales Market Share by Type (2016-2026)
Figure 45. North America COPD Drugs Sales Market Share by Application (2016-2026)
Figure 46. North America COPD Drugs Revenue Market Share by Country (2016-2026)
Figure 47. United States COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe COPD Drugs Sales Market Share by Type (2016-2026)
Figure 51. Europe COPD Drugs Sales Market Share by Application (2016-2026)
Figure 52. Europe COPD Drugs Revenue Market Share by Country (2016-2026)
Figure 53. Germany COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific COPD Drugs Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific COPD Drugs Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific COPD Drugs Revenue Market Share by Region (2016-2026)
Figure 61. China COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America COPD Drugs Sales Market Share by Type (2016-2026)
Figure 68. South America COPD Drugs Sales Market Share by Application (2016-2026)
Figure 69. South America COPD Drugs Revenue Market Share by Country (2016-2026)
Figure 70. Brazil COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa COPD Drugs Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa COPD Drugs Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa COPD Drugs Revenue Market Share by Country (2016-2026)
Figure 75. Turkey COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE COPD Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
世界のCOPD治療薬市場規模・現状・予測（2021年-2027年） COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors， steroids, combination therapies, etc. One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to tre…- 世界のCOPD治療薬市場規模・現状・予測（2021年-2027年） COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors， steroids, combination therapies, etc. One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to tre…
- 世界の喘息＆COPD薬市場 2021：企業別、地域別、種類・用途別 The Asthma and COPD Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulation…
- 世界の喘息/ COPD併用薬市場 2021：企業別、地域別、種類・用途別 The Asthma/COPD Combination Medication market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
- 世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disorder (COPD) Market The global Chronic Obstructive Pulmonary Disorder (COPD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy…